A Study on the Long-term Non-small Cell Lung Cancer Survivors 
in the Expand Access Program of Gefitinib in China

A Study on the Long-term Non-small Cell Lung Cancer Survivors 
in the Expand Access Program of Gefitinib in China

Background and objective The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary obje...

Full description

Bibliographic Details
Main Authors: Longyun LI, Wei ZHONG, Meilin LIAO, Li CHEN, Baohui HAN, Zhongzhen GUAN, Shiying YU, Xuyi LIU, Yilong WU, Guoliang JIANG, Jianming XU, Jia CHEN, Min TAO, Rongcheng LUO, Weimin LI, Nong XU, Xiao ZHAO, Mengzhao WANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-06-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Gefitinib
Expand Access Program (EAP)
Long-term survival
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.03

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.03

Similar Items